NCT04720430Completed
Blood Sample Collection for Experimental Blood Test to Track Liver Cancer
Circulating MicroRNA Levels as a Predictor of Successful Bridging or Down-Staging Loco-Regional Therapy (LRT) to Liver Transplantation for Patients With Hepatocellular Carcinoma (HCC)
Source: ClinicalTrials.gov · Last updated 29 Apr 2025
Brief summary (registry, in English)
This study investigates if an experimental blood test can help predict how well cancer will remain under control with treatment. Ther experimental blood test involves measuring mircoRNAs. MicroRNAs are small molecules which help regulate how genes are expressed. This information may help researchers guide treatment for other patients in the future.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 7 (actual)
- First submitted
- 7 Dec 2020
- Start date
- 3 Dec 2019
- Primary completion date
- 15 Feb 2023
- Lead sponsor
- Thomas Jefferson University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT04720430
What you commit to
- Study type: Observational
- Participants enrolled: 7
- From 3 Dec 2019 to the primary completion date, 15 Feb 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior liver transplantation
- Active or prior systemic therapy for HCC
Other illness
- Either active or recent solid organ cancer other than hepatocellur carcinoma (HCC) within the last 5 years, unless determined by transplant hepatology team not to represent contra-indication to liver transplantation
- Contra-indication to LRT (as assessed by interventional radiologist, for example severe thrombocytopenia, severe vascular disease precluding access, etc)
Who the study is looking for
- Provide signed and dated informed consent form
- Willing to comply with all study procedures and be available for the duration of the study
- Definite diagnosis of hepatocellular carcinoma established (by standard radiographic or histologic criteria)
- Felt to be reasonable candidate for liver transplantation, potentially contingent on success of down-staging therapy
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Thomas Jefferson University Hospital Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.